Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Galiximab + Rituximab vs Rituximab for Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma
2005-003836-22Phase 3Completed
- Sponsor
- Biogen
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) comparing Galiximab + Rituximab with Rituximab + Placebo (2 arms). Primary endpoint: Progression-Free Survival. Started Jul 2006; status: completed.
02
Drugs
galiximab
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2005-003836-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003836-22.